SGLT2 inhibitors were linked to better kidney outcomes than GLP-1 receptor agonists in Type 2 diabetes. Learn more about the ...

In patients with diabetes, sustained use of GLP-1 receptor agonists is associated with a modestly higher risk for new-onset ...

Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in type 2 diabetes, their comparative effects on kidney ...

Patients with SGLT2 inhibitor-associated diabetic ketoacidosis (DKA) received significantly lower doses of insulin in the first 24 hours of treatment compared with patients with type 1 diabetes DKA, ...

Explore the potential of SGLT2 inhibitors for IgAN. Learn how these diabetes drugs slow kidney damage progression when added to standard treatment.

A fast-aging fish is giving scientists a rare, accelerated look at how kidneys grow old—and how a common drug may slow that ...

The SGLT2 inhibitors market is experiencing robust growth, driven by the rising prevalence of type 2 diabetes and chronic kidney disease worldwide. Additionally, the expected launch of emerging SGLT2 ...

Please provide your email address to receive an email when new articles are posted on . Patients who received pharmacy consultation were more likely to be prescribed an SGLT2 inhibitor. More patients ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “Sodium-glucose transport protein 2 (SGLT2) inhibitor ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors used for the treatment of type 2 diabetes, and for heart failure, are associated with a nearly threefold increased risk for diabetic ketoacidosis (DKA ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide a beneficial choice of treatment for patients with type 2 diabetes (diabetes mellitus/T2DM). It can be used as an alternative for those who ...